Yahoo Finance • 12 months ago
CAMBRIDGE, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced... Full story
Yahoo Finance • 12 months ago
CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined ra... Full story
Yahoo Finance • 12 months ago
― Completed enrollment in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD); expect to report topline data in the fourth quarter of 2024 ― ― U.S. Food and Drug Administration (FDA) lifted clinical hold... Full story
Yahoo Finance • last year
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with geneti... Full story
Yahoo Finance • last year
CAMBRIDGE, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announce... Full story
Yahoo Finance • last year
NEW YORK, Sept. 09, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegation... Full story
Yahoo Finance • last year
CAMBRIDGE, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced... Full story
Yahoo Finance • last year
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced... Full story
Yahoo Finance • last year
BENSALEM, Pa., June 27, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story
Yahoo Finance • last year
NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to... Full story
Yahoo Finance • last year
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) alleging that the Company violated federal secur... Full story
Yahoo Finance • last year
LOS ANGELES, June 26, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story
Yahoo Finance • last year
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. (“Fulcrum” or the “Company”) (NASDAQ: F... Full story
Yahoo Finance • last year
NEW YORK, June 25, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. (“Fulcrum” or the “Company”) (NASDAQ: FULC), and certain officers. The class action, file... Full story
Yahoo Finance • last year
NEW YORK, June 25, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Edgio, Inc. (NASDAQ: EGIO... Full story
Yahoo Finance • last year
NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusiv... Full story
Yahoo Finance • last year
NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to... Full story
Yahoo Finance • last year
LOS ANGELES, June 22, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 27, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or... Full story
Yahoo Finance • last year
LOS ANGELES, June 22, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Fulcrum Therapeutics, Inc. (“Fulcrum” or the “Company”) (NASDAQ: FULC). investors that a lawsuit filed on behalf of investors that purchased Fulcrum securities b... Full story
Yahoo Finance • last year
NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- Alphabet Inc. (NASDAQ: GOOG) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Com... Full story